Metabolic Profile of the Genome-Reduced Bacillus subtilis Strain IIG-Bs-27-39: An Attractive Chassis for Recombinant Protein Production

The Gram-positive bacterium Bacillus subtilis is extensively used in the industry for the secretory production of proteins with commercial value. To further improve its performance, this microbe has been the subject of extensive genome engineering efforts, especially the removal of large genomic reg...

Full description

Saved in:
Bibliographic Details
Published inACS Synthetic Biology Vol. 13; no. 7; pp. 2199 - 2214
Main Authors Aguilar Suárez, Rocío, Kohlstedt, Michael, Öktem, Ayşegül, Neef, Jolanda, Wu, Yuzheng, Ikeda, Kaiya, Yoshida, Ken-Ichi, Altenbuchner, Josef, Wittmann, Christoph, van Dijl, Jan Maarten
Format Journal Article
LanguageEnglish
Published United States American Chemical Society 19.07.2024
American Chemical Society (ACS)
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The Gram-positive bacterium Bacillus subtilis is extensively used in the industry for the secretory production of proteins with commercial value. To further improve its performance, this microbe has been the subject of extensive genome engineering efforts, especially the removal of large genomic regions that are dispensable or even counterproductive. Here, we present the genome-reduced B. subtilis strain IIG-Bs-27-39, which was obtained through systematic deletion of mobile genetic elements, as well as genes for extracellular proteases, sporulation, flagella formation, and antibiotic production. Different from previously characterized genome-reduced B. subtilis strains, the IIG-Bs-27-39 strain was still able to grow on minimal media. We used this feature to benchmark strain IIG-Bs-27-39 against its parental strain 168 with respect to heterologous protein production and metabolic parameters during bioreactor cultivation. The IIG-Bs-27-39 strain presented superior secretion of difficult-to-produce staphylococcal antigens, as well as higher specific growth rates and biomass yields. At the metabolic level, changes in byproduct formation and internal amino acid pools were observed, whereas energetic parameters such as the ATP yield, ATP/ADP levels, and adenylate energy charge were comparable between the two strains. Intriguingly, we observed a significant increase in the total cellular NADPH level during all tested conditions and increases in the NAD+ and NADP­(H) pools during protein production. This indicates that the IIG-Bs-27-39 strain has more energy available for anabolic processes and protein production, thereby providing a link between strain physiology and production performance. On this basis, we conclude that the genome-reduced strain IIG-Bs-27-39 represents an attractive chassis for future biotechnological applications.
AbstractList The Gram-positive bacterium Bacillus subtilis is extensively used in the industry for the secretory production of proteins with commercial value. To further improve its performance, this microbe has been the subject of extensive genome engineering efforts, especially the removal of large genomic regions that are dispensable or even counterproductive. Here, we present the genome-reduced B. subtilis strain IIG-Bs-27-39, which was obtained through systematic deletion of mobile genetic elements, as well as genes for extracellular proteases, sporulation, flagella formation, and antibiotic production. Different from previously characterized genome-reduced B. subtilis strains, the IIG-Bs-27-39 strain was still able to grow on minimal media. We used this feature to benchmark strain IIG-Bs-27-39 against its parental strain 168 with respect to heterologous protein production and metabolic parameters during bioreactor cultivation. The IIG-Bs-27-39 strain presented superior secretion of difficult-to-produce staphylococcal antigens, as well as higher specific growth rates and biomass yields. At the metabolic level, changes in byproduct formation and internal amino acid pools were observed, whereas energetic parameters such as the ATP yield, ATP/ADP levels, and adenylate energy charge were comparable between the two strains. Intriguingly, we observed a significant increase in the total cellular NADPH level during all tested conditions and increases in the NAD+ and NADP(H) pools during protein production. This indicates that the IIG-Bs-27-39 strain has more energy available for anabolic processes and protein production, thereby providing a link between strain physiology and production performance. On this basis, we conclude that the genome-reduced strain IIG-Bs-27-39 represents an attractive chassis for future biotechnological applications.The Gram-positive bacterium Bacillus subtilis is extensively used in the industry for the secretory production of proteins with commercial value. To further improve its performance, this microbe has been the subject of extensive genome engineering efforts, especially the removal of large genomic regions that are dispensable or even counterproductive. Here, we present the genome-reduced B. subtilis strain IIG-Bs-27-39, which was obtained through systematic deletion of mobile genetic elements, as well as genes for extracellular proteases, sporulation, flagella formation, and antibiotic production. Different from previously characterized genome-reduced B. subtilis strains, the IIG-Bs-27-39 strain was still able to grow on minimal media. We used this feature to benchmark strain IIG-Bs-27-39 against its parental strain 168 with respect to heterologous protein production and metabolic parameters during bioreactor cultivation. The IIG-Bs-27-39 strain presented superior secretion of difficult-to-produce staphylococcal antigens, as well as higher specific growth rates and biomass yields. At the metabolic level, changes in byproduct formation and internal amino acid pools were observed, whereas energetic parameters such as the ATP yield, ATP/ADP levels, and adenylate energy charge were comparable between the two strains. Intriguingly, we observed a significant increase in the total cellular NADPH level during all tested conditions and increases in the NAD+ and NADP(H) pools during protein production. This indicates that the IIG-Bs-27-39 strain has more energy available for anabolic processes and protein production, thereby providing a link between strain physiology and production performance. On this basis, we conclude that the genome-reduced strain IIG-Bs-27-39 represents an attractive chassis for future biotechnological applications.
The Gram-positive bacterium Bacillus subtilis is extensively used in the industry for the secretory production of proteins with commercial value. To further improve its performance, this microbe has been the subject of extensive genome engineering efforts, especially the removal of large genomic regions that are dispensable or even counterproductive. Here, we present the genome-reduced B. subtilis strain IIG-Bs-27-39, which was obtained through systematic deletion of mobile genetic elements, as well as genes for extracellular proteases, sporulation, flagella formation, and antibiotic production. Different from previously characterized genome-reduced B. subtilis strains, the IIG-Bs-27-39 strain was still able to grow on minimal media. We used this feature to benchmark strain IIG-Bs-27-39 against its parental strain 168 with respect to heterologous protein production and metabolic parameters during bioreactor cultivation. The IIG-Bs-27-39 strain presented superior secretion of difficult-to-produce staphylococcal antigens, as well as higher specific growth rates and biomass yields. At the metabolic level, changes in byproduct formation and internal amino acid pools were observed, whereas energetic parameters such as the ATP yield, ATP/ADP levels, and adenylate energy charge were comparable between the two strains. Intriguingly, we observed a significant increase in the total cellular NADPH level during all tested conditions and increases in the NAD + and NADP(H) pools during protein production. This indicates that the IIG-Bs-27-39 strain has more energy available for anabolic processes and protein production, thereby providing a link between strain physiology and production performance. On this basis, we conclude that the genome-reduced strain IIG-Bs-27-39 represents an attractive chassis for future biotechnological applications.
The Gram-positive bacterium Bacillus subtilis is extensively used in the industry for the secretory production of proteins with commercial value. To further improve its performance, this microbe has been the subject of extensive genome engineering efforts, especially the removal of large genomic regions that are dispensable or even counterproductive. Here, we present the genome-reduced B. subtilis strain IIG-Bs-27-39, which was obtained through systematic deletion of mobile genetic elements, as well as genes for extracellular proteases, sporulation, flagella formation, and antibiotic production. Different from previously characterized genome-reduced B. subtilis strains, the IIG-Bs-27-39 strain was still able to grow on minimal media. We used this feature to benchmark strain IIG-Bs-27-39 against its parental strain 168 with respect to heterologous protein production and metabolic parameters during bioreactor cultivation. The IIG-Bs-27-39 strain presented superior secretion of difficult-to-produce staphylococcal antigens, as well as higher specific growth rates and biomass yields. At the metabolic level, changes in byproduct formation and internal amino acid pools were observed, whereas energetic parameters such as the ATP yield, ATP/ADP levels, and adenylate energy charge were comparable between the two strains. Intriguingly, we observed a significant increase in the total cellular NADPH level during all tested conditions and increases in the NAD+ and NADP­(H) pools during protein production. This indicates that the IIG-Bs-27-39 strain has more energy available for anabolic processes and protein production, thereby providing a link between strain physiology and production performance. On this basis, we conclude that the genome-reduced strain IIG-Bs-27-39 represents an attractive chassis for future biotechnological applications.
The Gram-positive bacterium is extensively used in the industry for the secretory production of proteins with commercial value. To further improve its performance, this microbe has been the subject of extensive genome engineering efforts, especially the removal of large genomic regions that are dispensable or even counterproductive. Here, we present the genome-reduced strain IIG-Bs-27-39, which was obtained through systematic deletion of mobile genetic elements, as well as genes for extracellular proteases, sporulation, flagella formation, and antibiotic production. Different from previously characterized genome-reduced strains, the IIG-Bs-27-39 strain was still able to grow on minimal media. We used this feature to benchmark strain IIG-Bs-27-39 against its parental strain 168 with respect to heterologous protein production and metabolic parameters during bioreactor cultivation. The IIG-Bs-27-39 strain presented superior secretion of difficult-to-produce staphylococcal antigens, as well as higher specific growth rates and biomass yields. At the metabolic level, changes in byproduct formation and internal amino acid pools were observed, whereas energetic parameters such as the ATP yield, ATP/ADP levels, and adenylate energy charge were comparable between the two strains. Intriguingly, we observed a significant increase in the total cellular NADPH level during all tested conditions and increases in the NAD and NADP(H) pools during protein production. This indicates that the IIG-Bs-27-39 strain has more energy available for anabolic processes and protein production, thereby providing a link between strain physiology and production performance. On this basis, we conclude that the genome-reduced strain IIG-Bs-27-39 represents an attractive chassis for future biotechnological applications.
Author Öktem, Ayşegül
Altenbuchner, Josef
Kohlstedt, Michael
Wittmann, Christoph
Ikeda, Kaiya
Wu, Yuzheng
Neef, Jolanda
van Dijl, Jan Maarten
Aguilar Suárez, Rocío
Yoshida, Ken-Ichi
AuthorAffiliation Institute for Systems Biotechnology
Institute for Industrial Genetics
University Medical Center Groningen-University of Groningen
Department of Medical Microbiology
Department of Science, Technology and Innovation
AuthorAffiliation_xml – name: Department of Medical Microbiology
– name: Department of Science, Technology and Innovation
– name: Institute for Industrial Genetics
– name: Institute for Systems Biotechnology
– name: University Medical Center Groningen-University of Groningen
Author_xml – sequence: 1
  givenname: Rocío
  orcidid: 0000-0003-4452-065X
  surname: Aguilar Suárez
  fullname: Aguilar Suárez, Rocío
  organization: University Medical Center Groningen-University of Groningen
– sequence: 2
  givenname: Michael
  surname: Kohlstedt
  fullname: Kohlstedt, Michael
  organization: Institute for Systems Biotechnology
– sequence: 3
  givenname: Ayşegül
  surname: Öktem
  fullname: Öktem, Ayşegül
  organization: University Medical Center Groningen-University of Groningen
– sequence: 4
  givenname: Jolanda
  surname: Neef
  fullname: Neef, Jolanda
  organization: University Medical Center Groningen-University of Groningen
– sequence: 5
  givenname: Yuzheng
  surname: Wu
  fullname: Wu, Yuzheng
  organization: Department of Science, Technology and Innovation
– sequence: 6
  givenname: Kaiya
  surname: Ikeda
  fullname: Ikeda, Kaiya
  organization: Department of Science, Technology and Innovation
– sequence: 7
  givenname: Ken-Ichi
  surname: Yoshida
  fullname: Yoshida, Ken-Ichi
  organization: Department of Science, Technology and Innovation
– sequence: 8
  givenname: Josef
  surname: Altenbuchner
  fullname: Altenbuchner, Josef
  organization: Institute for Industrial Genetics
– sequence: 9
  givenname: Christoph
  surname: Wittmann
  fullname: Wittmann, Christoph
  organization: Institute for Systems Biotechnology
– sequence: 10
  givenname: Jan Maarten
  orcidid: 0000-0002-5688-8438
  surname: van Dijl
  fullname: van Dijl, Jan Maarten
  email: j.m.van.dijl01@umcg.nl
  organization: University Medical Center Groningen-University of Groningen
BackLink https://cir.nii.ac.jp/crid/1871710641474086656$$DView record in CiNii
https://www.ncbi.nlm.nih.gov/pubmed/38981062$$D View this record in MEDLINE/PubMed
BookMark eNp9kc1u1DAUhSNURH_oA7BBXrBgk-Jrxz9hg6YjGEYqAhVYW47jMK48domdSn0CXruOZhgVFvXC19L9zrnWPafVUYjBVtUrwBeACbzTJqX70Ll40RiMCWueVScEONQMc3r06H1cnad0g8thjDIqX1THVLYSMCcn1Z8vNusuemfQtzEOzlsUB5Q3Fq1siFtbX9t-MrZHl9o476eE0tRl511C3_OoXUDr9aq-TDURNW3fo0VAi1waJrs7i5YbnVJBhziia2vitnNBhzyPyrZoSy3u2cXwsno-aJ_s-b6eVT8_ffyx_FxffV2tl4urWjNKcw16aDstCQbMMAyaArEtb9oWGBjacSY6JnnbUSJBQMc47gUGiQetiZC0p2fVh53v7dRtbW9sKJ_16nZ0Wz3eq6id-rcT3Eb9incKgPCGElYc3u4dxvh7simrrUvGeq-DjVNSFAvRypaKpqCvHw87TPm7_gLADjBjTGm0wwEBrOaU1SFltU-5aMR_GuOynnc45-GfVL7ZKYNzRTTfIEXZE-YNNKLBknPGC1bvsOKgbuI0hhLIE7YPsbrItg
CitedBy_id crossref_primary_10_3390_microorganisms13010060
Cites_doi 10.15252/msb.20156608
10.1016/j.jbiotec.2017.05.024
10.1111/j.1365-2958.2004.04386.x
10.1093/molbev/msg219
10.1128/aem.71.12.8818-8824.2005
10.1016/j.ab.2010.03.003
10.1128/mr.59.1.48-62.1995
10.1021/acssynbio.7b00261
10.1101/gr.217202
10.1016/j.nbt.2023.12.009
10.1016/j.ijmm.2014.11.002
10.1016/j.ymben.2023.09.003
10.1186/s12934-014-0129-9
10.1016/j.ymben.2021.09.002
10.1002/cbic.201300332
10.1016/j.ymben.2023.03.006
10.1111/1462-2920.12309
10.1128/AEM.01634-13
10.1128/mSystems.00655-21
10.1186/1475-2859-12-69
10.1186/s12934-017-0684-y
10.1186/s12934-019-1218-6
10.1111/1751-7915.13660
10.1111/1462-2920.12438
10.3389/fmicb.2015.01431
10.1186/s12934-022-02003-z
10.1371/journal.pone.0164314
10.1016/j.ab.2004.01.002
10.1042/bst20160436
10.1016/j.tibtech.2021.10.003
10.1038/s41598-017-08182-9
10.1021/acssynbio.3c00444
10.1021/acssynbio.1c00339
10.1038/ng1555
10.1021/bi00851a033
10.1007/s10529-008-9789-z
10.1046/j.1365-2958.2003.03565.x
10.1093/nar/gkab943
10.1146/annurev-chembioeng-060718-030332
10.1186/s13568-019-0806-5
10.1186/s12934-017-0735-4
10.1126/science.1126439
10.1111/j.1574-6976.2008.00151.x
10.1038/s41467-019-12961-5
10.1073/pnas.1718622115
10.1042/BA20060111
10.1186/s12934-017-0764-z
10.1002/macp.200500213
10.1007/s00253-014-6030-y
10.1038/36786
10.1186/1475-2859-12-18
10.1016/j.ab.2005.01.027
10.1073/pnas.44.10.1072
10.1128/AEM.06136-11
10.1016/j.ymben.2022.05.001
10.3389/fbioe.2020.00143
10.1073/pnas.86.7.2172
10.1128/MMBR.00029-16
10.1016/j.ymben.2006.10.002
10.1128/AAC.01144-10
10.1186/s12934-015-0207-7
10.1021/acssynbio.0c00194
10.1039/C8GC01901K
10.1186/1475-2859-11-122
10.1016/0378-1119(85)90120-9
10.1186/s12864-017-4127-2
10.1080/21505594.2017.1294297
10.1101/gr.215293.116
10.1186/s12934-014-0159-3
10.1016/j.jbiotec.2012.06.034
10.1126/science.1206871
10.1002/biot.201400041
10.1099/mic.0.000150
10.3389/fbioe.2022.942304
10.1021/acssynbio.8b00342
10.1016/j.tim.2008.03.004
10.1021/ac0623888
10.1186/s12934-023-02044-y
10.1186/s12934-016-0494-7
10.1016/j.bbamcr.2004.04.009
ContentType Journal Article
Copyright 2024 The Authors. Published by American Chemical Society
2024 The Authors. Published by American Chemical Society 2024 The Authors
Copyright_xml – notice: 2024 The Authors. Published by American Chemical Society
– notice: 2024 The Authors. Published by American Chemical Society 2024 The Authors
DBID RYH
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.1021/acssynbio.4c00254
DatabaseName CiNii Complete
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic


MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Engineering
DocumentTitleAlternate An Attractive Chassis for Recombinant Protein Production
EISSN 2161-5063
EndPage 2214
ExternalDocumentID PMC11264325
38981062
10_1021_acssynbio_4c00254
a128521379
Genre Journal Article
GroupedDBID 53G
55A
7~N
AABXI
ABFRP
ABMVS
ABQRX
ABUCX
ACGFS
ACS
ADHLV
AEESW
AENEX
AFEFF
AHGAQ
ALMA_UNASSIGNED_HOLDINGS
AQSVZ
BAANH
CUPRZ
EBS
ED~
GGK
GNL
IH9
JG~
ROL
UI2
VF5
VG9
W1F
ABBLG
ABJNI
ABLBI
RYH
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ID FETCH-LOGICAL-a533t-1af9ba82010501fa312e96499151c3b657b5869b328171b560d70180faa2783d3
IEDL.DBID ACS
ISSN 2161-5063
IngestDate Thu Aug 21 18:33:40 EDT 2025
Fri Jul 11 16:36:00 EDT 2025
Mon Jul 21 05:55:53 EDT 2025
Tue Jul 01 02:19:44 EDT 2025
Thu Apr 24 22:59:10 EDT 2025
Thu Jun 26 21:26:53 EDT 2025
Mon Jul 22 05:24:56 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 7
Keywords energetic parameters
genome reduction
metabolic features
Bacillus subtilis
Language English
License https://creativecommons.org/licenses/by/4.0
Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (https://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-a533t-1af9ba82010501fa312e96499151c3b657b5869b328171b560d70180faa2783d3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-5688-8438
0000-0003-4452-065X
0000-0003-4452-065x
0000-0001-7828-999x
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC11264325
PMID 38981062
PQID 3077989374
PQPubID 23479
PageCount 16
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_11264325
proquest_miscellaneous_3077989374
pubmed_primary_38981062
crossref_primary_10_1021_acssynbio_4c00254
crossref_citationtrail_10_1021_acssynbio_4c00254
nii_cinii_1871710641474086656
acs_journals_10_1021_acssynbio_4c00254
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2024-07-19
PublicationDateYYYYMMDD 2024-07-19
PublicationDate_xml – month: 07
  year: 2024
  text: 2024-07-19
  day: 19
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle ACS Synthetic Biology
PublicationTitleAlternate ACS Synth. Biol
PublicationYear 2024
Publisher American Chemical Society
American Chemical Society (ACS)
Publisher_xml – name: American Chemical Society
– name: American Chemical Society (ACS)
References ref9/cit9
ref45/cit45
ref3/cit3
ref27/cit27
Yoshida K. (ref21/cit21) 2020
ref81/cit81
ref63/cit63
ref56/cit56
ref16/cit16
ref52/cit52
ref23/cit23
ref8/cit8
ref31/cit31
ref59/cit59
ref77/cit77
ref34/cit34
ref71/cit71
ref37/cit37
ref20/cit20
ref48/cit48
ref60/cit60
ref74/cit74
ref17/cit17
ref82/cit82
ref10/cit10
ref35/cit35
ref53/cit53
ref19/cit19
ref42/cit42
ref46/cit46
ref49/cit49
ref13/cit13
ref61/cit61
ref75/cit75
ref67/cit67
ref24/cit24
ref38/cit38
ref50/cit50
ref64/cit64
ref78/cit78
ref54/cit54
ref6/cit6
ref36/cit36
ref18/cit18
ref83/cit83
ref65/cit65
ref79/cit79
ref11/cit11
ref25/cit25
Wittmann C. (ref2/cit2) 2017; 1
ref29/cit29
ref72/cit72
ref76/cit76
ref32/cit32
ref39/cit39
ref14/cit14
ref57/cit57
ref5/cit5
ref51/cit51
ref43/cit43
ref80/cit80
ref28/cit28
ref40/cit40
ref68/cit68
ref26/cit26
ref55/cit55
ref73/cit73
ref69/cit69
ref12/cit12
ref15/cit15
ref62/cit62
ref66/cit66
ref41/cit41
ref58/cit58
ref22/cit22
ref33/cit33
ref4/cit4
ref30/cit30
ref47/cit47
ref1/cit1
ref44/cit44
ref70/cit70
ref7/cit7
References_xml – ident: ref53/cit53
  doi: 10.15252/msb.20156608
– ident: ref63/cit63
  doi: 10.1016/j.jbiotec.2017.05.024
– volume: 1
  volume-title: Industrial Biotechnology
  year: 2017
  ident: ref2/cit2
– ident: ref9/cit9
  doi: 10.1111/j.1365-2958.2004.04386.x
– ident: ref58/cit58
  doi: 10.1093/molbev/msg219
– ident: ref35/cit35
  doi: 10.1128/aem.71.12.8818-8824.2005
– ident: ref83/cit83
  doi: 10.1016/j.ab.2010.03.003
– ident: ref37/cit37
  doi: 10.1128/mr.59.1.48-62.1995
– ident: ref8/cit8
  doi: 10.1021/acssynbio.7b00261
– ident: ref10/cit10
  doi: 10.1101/gr.217202
– ident: ref70/cit70
– ident: ref39/cit39
  doi: 10.1016/j.nbt.2023.12.009
– ident: ref34/cit34
  doi: 10.1016/j.ijmm.2014.11.002
– ident: ref73/cit73
  doi: 10.1016/j.ymben.2023.09.003
– ident: ref45/cit45
  doi: 10.1186/s12934-014-0129-9
– ident: ref15/cit15
  doi: 10.1016/j.ymben.2021.09.002
– ident: ref55/cit55
  doi: 10.1002/cbic.201300332
– ident: ref72/cit72
  doi: 10.1016/j.ymben.2023.03.006
– ident: ref23/cit23
  doi: 10.1111/1462-2920.12309
– ident: ref27/cit27
  doi: 10.1128/AEM.01634-13
– ident: ref36/cit36
  doi: 10.1128/mSystems.00655-21
– ident: ref50/cit50
  doi: 10.1186/1475-2859-12-69
– start-page: 872
  volume-title: Biotechnology and Bioprocess Engineering
  year: 2020
  ident: ref21/cit21
– ident: ref71/cit71
  doi: 10.1186/s12934-017-0684-y
– ident: ref77/cit77
  doi: 10.1186/s12934-019-1218-6
– ident: ref16/cit16
  doi: 10.1111/1751-7915.13660
– ident: ref47/cit47
  doi: 10.1111/1462-2920.12438
– ident: ref68/cit68
  doi: 10.3389/fmicb.2015.01431
– ident: ref74/cit74
  doi: 10.1186/s12934-022-02003-z
– ident: ref25/cit25
  doi: 10.1371/journal.pone.0164314
– ident: ref81/cit81
  doi: 10.1016/j.ab.2004.01.002
– ident: ref54/cit54
  doi: 10.1042/bst20160436
– ident: ref4/cit4
  doi: 10.1016/j.tibtech.2021.10.003
– ident: ref32/cit32
  doi: 10.1038/s41598-017-08182-9
– ident: ref40/cit40
  doi: 10.1021/acssynbio.3c00444
– ident: ref60/cit60
  doi: 10.1021/acssynbio.1c00339
– ident: ref24/cit24
  doi: 10.1038/ng1555
– ident: ref38/cit38
  doi: 10.1021/bi00851a033
– ident: ref80/cit80
  doi: 10.1007/s10529-008-9789-z
– ident: ref62/cit62
  doi: 10.1046/j.1365-2958.2003.03565.x
– ident: ref69/cit69
  doi: 10.1093/nar/gkab943
– ident: ref3/cit3
  doi: 10.1146/annurev-chembioeng-060718-030332
– ident: ref29/cit29
  doi: 10.1186/s13568-019-0806-5
– ident: ref76/cit76
  doi: 10.1186/s12934-017-0735-4
– ident: ref7/cit7
  doi: 10.1126/science.1126439
– ident: ref26/cit26
  doi: 10.1111/j.1574-6976.2008.00151.x
– ident: ref79/cit79
  doi: 10.1038/s41467-019-12961-5
– ident: ref5/cit5
  doi: 10.1073/pnas.1718622115
– ident: ref28/cit28
  doi: 10.1042/BA20060111
– ident: ref49/cit49
  doi: 10.1186/s12934-017-0764-z
– ident: ref1/cit1
  doi: 10.1002/macp.200500213
– ident: ref65/cit65
  doi: 10.1007/s00253-014-6030-y
– ident: ref57/cit57
  doi: 10.1038/36786
– ident: ref52/cit52
  doi: 10.1186/1475-2859-12-18
– ident: ref82/cit82
  doi: 10.1016/j.ab.2005.01.027
– ident: ref67/cit67
  doi: 10.1073/pnas.44.10.1072
– ident: ref51/cit51
  doi: 10.1128/AEM.06136-11
– ident: ref17/cit17
  doi: 10.1016/j.ymben.2022.05.001
– ident: ref31/cit31
  doi: 10.3389/fbioe.2020.00143
– ident: ref66/cit66
  doi: 10.1073/pnas.86.7.2172
– ident: ref12/cit12
  doi: 10.1128/MMBR.00029-16
– ident: ref19/cit19
  doi: 10.1016/j.ymben.2006.10.002
– ident: ref33/cit33
  doi: 10.1128/AAC.01144-10
– ident: ref18/cit18
  doi: 10.1186/s12934-015-0207-7
– ident: ref20/cit20
  doi: 10.1021/acssynbio.0c00194
– ident: ref75/cit75
  doi: 10.1039/C8GC01901K
– ident: ref46/cit46
  doi: 10.1186/1475-2859-11-122
– ident: ref61/cit61
  doi: 10.1016/0378-1119(85)90120-9
– ident: ref30/cit30
  doi: 10.1186/s12864-017-4127-2
– ident: ref64/cit64
  doi: 10.1080/21505594.2017.1294297
– ident: ref43/cit43
  doi: 10.1101/gr.215293.116
– ident: ref11/cit11
  doi: 10.1186/s12934-014-0159-3
– ident: ref42/cit42
  doi: 10.1016/j.jbiotec.2012.06.034
– ident: ref56/cit56
  doi: 10.1126/science.1206871
– ident: ref13/cit13
  doi: 10.1002/biot.201400041
– ident: ref59/cit59
  doi: 10.1099/mic.0.000150
– ident: ref78/cit78
  doi: 10.3389/fbioe.2022.942304
– ident: ref6/cit6
  doi: 10.1021/acssynbio.8b00342
– ident: ref22/cit22
  doi: 10.1016/j.tim.2008.03.004
– ident: ref48/cit48
  doi: 10.1021/ac0623888
– ident: ref14/cit14
  doi: 10.1186/s12934-023-02044-y
– ident: ref44/cit44
  doi: 10.1186/s12934-016-0494-7
– ident: ref41/cit41
  doi: 10.1016/j.bbamcr.2004.04.009
SSID ssj0000553538
Score 2.33912
Snippet The Gram-positive bacterium Bacillus subtilis is extensively used in the industry for the secretory production of proteins with commercial value. To further...
The Gram-positive bacterium is extensively used in the industry for the secretory production of proteins with commercial value. To further improve its...
The Gram-positive bacterium Bacillus subtilis is extensively used in the industry for the secretory production of proteins with commercial value. To further...
SourceID pubmedcentral
proquest
pubmed
crossref
nii
acs
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 2199
SubjectTerms Bacillus subtilis
Bacillus subtilis - genetics
Bacillus subtilis - metabolism
Bacterial Proteins - genetics
Bacterial Proteins - metabolism
Bioreactors
energetic parameters
genome reduction
Genome, Bacterial - genetics
Metabolic Engineering - methods
metabolic features
Metabolome
Recombinant Proteins - biosynthesis
Recombinant Proteins - genetics
Recombinant Proteins - metabolism
Title Metabolic Profile of the Genome-Reduced Bacillus subtilis Strain IIG-Bs-27-39: An Attractive Chassis for Recombinant Protein Production
URI http://dx.doi.org/10.1021/acssynbio.4c00254
https://cir.nii.ac.jp/crid/1871710641474086656
https://www.ncbi.nlm.nih.gov/pubmed/38981062
https://www.proquest.com/docview/3077989374
https://pubmed.ncbi.nlm.nih.gov/PMC11264325
Volume 13
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELZoucCB92OBIiMhDkheYidOYm7bFX0gFSFKpd4iO3HUiDSp6gQJ_gB_mxknG7qlqnpJpMQPZTL2fGN7viHkbVGWOtXcMGExJAcMNtOqDJkRAp5H2iifteTgS7x3FH0-lsf_eLYv7-AL_kHnzv1qTNXOo9zHbm-Q2yJOE_S0FsvDaUElkDKUPnO1ABTDJNje1S7mVa2gNcrdmjXaaKrqKqB5-bzkBQO0c3-I7HaetxDPnfyY952Z57__Z3W8ybc9IPdGIEoXg-Y8JLds84jcvUBP-Jj8ObAd6Ehd5fTrkNqbtiUFxEh3bdOeWvYNeV9tQbd1XtV176jrTVfVlaOHPvUE3d_fZduOCZhh1Ee6aOii63xY1k9LlyeA26EooGaKTvCp8YdysCvMwIn3YqC2fUKOdj59X-6xMXED04AeO8Z1qYxGbBHIgJc65MKqGHwrgBd5aGKZGJnGyoQi5Qk3ALqKBInESq0x8UcRPiWbTdvY54QmCrTFWiFTE0YRuD-isCZPZWEDDqokZ-QdCDEbB57L_J664Nkk2WyU7IwEqz-d5SP9OYqivq7K-6nK2cD9cV3hLVAfaBqvHNxQgG5xxKMkCpBSMJ6RNyvFymAE47aMbmzbuwxm2UQhbIQ2ng2KNnUHcDKFdsSMpGsqOBVAdvD1N0114lnCMTYsCoV8cVMJvSR3BCA2XLjm6hXZ7M57uwWIqzOv_Uj7CxGEJXA
linkProvider American Chemical Society
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwzV3NbtQwELbacoAe-IcuUDAScEDyEjtxfpA4bBfaXdqtEG2l3oKdOGpEmiCcgMoL8B68Ci_G2MmGblVVXCpxSaTEcaLxjOeb2PMNQs_SLBOhoJIwZVJywGETEWUukYzBdU_IyFYtme36kwPv_SE_XEK_5rkw8BEaetJ2Ef8vuwB9Bdf0SSnzauglNoW720i5rU6-Q5im30zfwpg-Z2zz3f54QrpKAkQAnKkJFVkkhXF2DndoJlzKVOQD2Ad_l7jS54HkoR9Jl4U0oBJQQBoYZqtMCFOJInWh32V0BcAPMwHeaLzX_8dxOHe5LZjNADwRDi5_vnh63lcbJ5joBSe4XOb5efj27DbNU35v8wb63UvMbnf5PGxqOUx-nCGT_L9FehNd72A3HrV2cgstqfI2Wj1FxngH_ZypGiyiyBP8oS1kjqsMAz7GW6qsjhX5aFhuVYo3RJIXRaOxbmSdF7nGe7bQBp5Ot8iGJgzm0-g1HpV4VNc2Ce2bwuMjiFKgKcQI2IT8x9JuQTKvMvVGzTltiXzvooNLkcQ9tFJWpVpDOIjANpRiPJSu50Gwx1Ilk5CnyqFgOHyAXsCgxd00o2O7g4DRuB_JuBvJAXLmChYnHdm7EUVx0SMv-0e-tEwnFzVeB62Frs2RQtANQNX3qBd4jiFQ9Afo6VyfY5ivzCKUKFXV6Bh8ShAZkAx93G_1u38dgOcQ-mEDFC5oft_AcKEv3inzI8uJbjLhPJfxB_8qoSfo6mR_thPvTHe3H6JrDLCq-WVPo0dopf7aqHXAmrV8bI0do0-XbQp_AAP5g4Y
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwzV3NbtQwELbaIiE48P-zQMFIwAEpS-zE-UHisN2y7VJaVZRKvQU7cdSINKlwFlRegDfhVXgtZpxs1K2qikslLomUOJPI9ni-iWe-IeRFlucykkw5XGNKDhhsR8a55yjO4bovVWyrlmzvBJv7_ocDcbBEfs9zYeAjDEgydhMftfo4yzuGAfYGrpuTShX10E9tGncXTLmlT36Aq2beTddhXF9yPnn_ebzpdNUEHAmQpnGYzGMl0eC5wmW59BjXcQCAH2xe6qlAhEpEQaw8HrGQKUACWYjsVrmUWI0i80DuMrmC24To5I3Ge_2_HFcIT9ii2RwAlCPA7M83UM_7ajSEqVkwhMtVUZyHcc-Gap6yfZOb5E_fazbk5etw1qhh-vMMoeT_3623yI0OftNRqy-3yZKu7pDrp0gZ75Jf27oBzSiLlO62Bc1pnVPAyXRDV_WRdj4h263O6JpMi7KcGWpmqinKwtA9W3CDTqcbzppxOKyr8Vs6quioaWwy2ndNx4fgrUBT8BUouv5HyoYi4auw7iies5bQ9x7Zv5SeuE9WqrrSDwkNY9ARrbmIlOf74PTxTKs0Epl2GSiQGJBXMGhJt9yYxEYScJb0I5l0Izkg7nySJWlH-o5dUV70yOv-keOW8eSixqswc0E0Hhk43wBYA5_5oe8ikWIwIM_nczqBdQs3o2Sl65lJwLaEMYJlkPGgneP96wBERyCHD0i0MPv7BsiJvninKg4tNzpmxPkeF4_-tYeekau765Pk43Rn6zG5xgGy4p97Fj8hK823mV4FyNmop1bfKfly2ZrwF82Yhgk
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Metabolic+Profile+of+the+Genome-Reduced+Bacillus+subtilis+Strain+IIG-Bs-27-39%3A+An+Attractive+Chassis+for+Recombinant+Protein+Production&rft.jtitle=ACS+synthetic+biology&rft.au=Aguilar+Su%C3%A1rez%2C+Roc%C3%ADo&rft.au=Kohlstedt%2C+Michael&rft.au=%C3%96ktem%2C+Ay%C5%9Feg%C3%BCl&rft.au=Neef%2C+Jolanda&rft.date=2024-07-19&rft.issn=2161-5063&rft.eissn=2161-5063&rft.volume=13&rft.issue=7&rft.spage=2199&rft_id=info:doi/10.1021%2Facssynbio.4c00254&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2161-5063&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2161-5063&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2161-5063&client=summon